Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis-Reference-Cited by-同舟云学术

Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis

Published:2020-01-25 Issue:7 Volume:59 Page:899-910
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

van der Galiën Ruben,Boveneind-Vrubleuskaya Natasha van’t,Peloquin Charles,Skrahina Alena,Touw Daan J.,Alffenaar Jan-Willem C.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-020-00860-8.pdf

Reference41 articles.

1. World Health Organization. Fact sheet no 104, March 2017 . Available from: https://www.who.int/tb/challenges/mdr/MDR-RR_TB_factsheet_2017.pdf?ua=1. [https://www.who.int/mediacentre/factsheets/fs104/en/Accessed 18 Mar 2019].

2. Zumla A. Tuberculosis. N Engl J Med. 2013;368:745–55.

3. Dowdy DW. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ. 2009;87(4):296–304.

4. Admad N. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392:821–34./

5. World Health Organization. Treatment guidelines for drug-resistant tuberculosis: 2011 update. Available from: https://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf?ua=1. [Accessed 26 Apr 2016]. [Accessed 12 Jan 2020].

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis;Antimicrobial Agents and Chemotherapy;2023-12-14

2. Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility;Tuberculosis;2023-07

3. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens;Antimicrobial Agents and Chemotherapy;2023-05-17

4. Infant Exposure to Antituberculosis Drugs via Breast Milk and Assessment of Potential Adverse Effects in Breastfed Infants: Critical Review of Data;Pharmaceutics;2023-04-13

5. The Correlations of Minimal Inhibitory Concentration Values of Anti-TB Drugs with Treatment Outcomes and Clinical Profiles in Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in China;Infection and Drug Resistance;2022-09